Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Pfizer Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK--(BUSINESS WIRE)--PFIZER INC. (NYSE: PFE) INVITES INVESTORS AND THE GENERAL PUBLIC TO LISTEN TO A WEBCAST OF A DISCUSSION WITH ALBERT BOURLA, CHAIRMAN AND CHIEF EXECUTIVE OFFICER, AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE ON MONDAY, SEPTEMBER 14, 2026 AT 10:45 A.M. EDT. TO LISTEN TO THE WEBCAST, VISIT OUR WEB SITE AT WWW.PFIZER.COM/INVESTORS. INFORMATION ON ACCESSING AND REGISTERING FOR THE WEBCAST WILL BE AVAILABLE AT WWW.PFIZER.COM/INVESTORS BEGINNING TODAY. THE.

PFIZER INVITES PUBLIC TO LISTEN TO WEBCAST OF PFIZER DISCUSSION AT HEALTHCARE CONFERENCE

2026-2027 COVID-19 VACCINE FORMULA TARGETS THE XFG VARIANT, IN LINE WITH FDA GUIDANCE TO MORE CLOSELY MATCH CONTEMPORARY CIRCULATING VARIANTS SHIPPING WILL BEGIN IMMEDIATELY TO ENSURE RAPID ACCESS TO THIS SEASON'S VACCINE NEW YORK AND MAINZ, GERMANY, AUGUST 27, 2026  PFIZER INC. (NYSE: PFE, PFIZER) AND BIONTECH SE (NASDAQ: BNTX, BIONTECH) ANNOUNCED TODAY THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED THE SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION (SBLA) FOR THE COMPANIES' 2026-2027 COVID-19 VACCINE FORMULA TARGETING THE XFG VARIANT (COMIRNATY XFG; COVID-19 VACCINE, MRNA) FOR USE IN ADULTS AGES 65 YEARS AND OLDER, AS WELL AS IN INDIVIDUALS AGES 5 THROUGH 64 YEARS WITH AT LEAST ONE UNDERLYING CONDITION THAT PUTS THEM AT HIGH RISK FOR SEVERE OUTCOMES FROM COVID-19.1 THE FDA APPROVAL IS BASED ON THE CUMULATIVE BODY OF EVIDENCE PREVIOUSLY SUBMITTED BY PFIZER AND BIONTECH THAT INCLUDES CLINICAL, NON-CLINICAL AND REAL-WORLD DATA SUPPORTING THE SAFETY AND EFFECTIVENESS OF COMIRNATY, AS WELL AS MANUFACTURING/QUALITY AND NON-CLINICAL DATA SHOWING THAT THE XFG-ADAPTED COVID-19 VACCINE GENERATED STRONG IMMUNE RESPONSES AGAINST CURRENTLY CIRCULATING SARS-COV-2 VARIANTS, INCLUDING XFG, XFG.1.1, NB.1.8.1, PQ.17, PQ.2.8.1 AND OTHER CONTEMPORARY LINEAGES.2 THE SELECTION OF THE XFG VARIANT IS BASED ON GUIDANCE FROM THE FDA AS THE PREFERRED COMPOSITION OF COVID-19 VACCINES FOR USE IN THE U.S. BEGINNING IN FALL 2026.3 THIS SEASON'S PFIZER AND BIONTECH COVID-19 VACCINE WILL BEGIN SHIPPING IMMEDIATELY AND WILL BE AVAILABLE IN PHARMACIES, HOSPITALS, AND CLINICS ACROSS THE U.S. IN THE COMING DAYS. TO DATE, MORE THAN FIVE BILLION DOSES OF COMIRNATY HAVE BEEN DISTRIBUTED GLOBALLY, AND IT CONTINUES TO DEMONSTRATE A FAVORABLE SAFETY AND EFFICACY PROFILE SUPPORTED BY EXTENSIVE REAL-WORLD EVIDENCE AS WELL AS CLINICAL, NON-CLINICAL, PHARMACOVIGILANCE, AND MANUFACTURING DATA.2 THE COVID-19 VACCINES BY PFIZER AND BIONTECH ARE BASED ON BIONTECH'S PROPRIETARY MRNA TECHNOLOGY AND WERE D

PFIZER AND BIONTECH RECEIVE U.S. FDA APPROVAL FOR XFG-ADAPTED COVID-19 VACCINE

NEW YORK & LYON, FRANCE, AUGUST, 14, 2026PFIZER INC. (NYSE: PFE) AND VALNEVA SE (NASDAQ: VALN; EURONEXT PARIS: VLA) TODAY ANNOUNCED THAT THE EUROPEAN MEDICINES AGENCY (EMA) HAS VALIDATED THE MARKETING AUTHORIZATION APPLICATION (MAA) FOR PF-07307405, THE COMPANIES' 6-VALENT OUTER SURFACE PROTEIN A (OSPA)-BASED LYME DISEASE VACCINE CANDIDATE AND WILL BEGIN ITS ASSESSMENT OF THE APPLICATION.

PFIZER AND VALNEVA'S LYME DISEASE VACCINE CANDIDATE MARKETING AUTHORIZATION APPLICATION VALIDATED BY EUROPEAN MEDICINES AGENCY

NEW YORK--(BUSINESS WIRE)--PFIZER INC. (NYSE: PFE) REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2026 AND RAISED ITS FULL-YEAR 2026 REVENUE GUIDANCE BY $500 MILLION AT THE MIDPOINT WHILE REAFFIRMING GUIDANCE(2) FOR ADJUSTED(3) DILUTED EPS, WHICH ABSORBS AN IMPACT OF APPROXIMATELY $0.10 RELATED TO THE INNOVENT BIOLOGICS, INC. TRANSACTION. EXECUTIVE COMMENTARY DR. ALBERT BOURLA, CHAIRMAN AND CEO OF PFIZER: PFIZER HAD ANOTHER STRONG QUARTER, DELIVERING ON OUR FINANCIAL COMMITMENTS AND ADVA.

PFIZER REPORTS SECOND-QUARTER RESULTS AND RAISES MIDPOINT OF 2026 REVENUE GUIDANCE

NEW YORK--(BUSINESS WIRE)--PFIZER INC. (NYSE: PFE) TODAY ANNOUNCED POSITIVE TOPLINE RESULTS FROM TWO PHASE 3 TRIALS EVALUATING THE EFFICACY AND SAFETY OF LITFULO ONCE DAILY IN PATIENTS WITH BOTH ACTIVE AND STABLE NONSEGMENTAL VITILIGO (NSV) AND WHO HAD A BROAD RANGE OF DISEASE SEVERITY. THE TRANQUILLO STUDY INCLUDED PATIENTS AGED 12 YEARS AND OLDER, WHILE TRANQUILLO 2 ENROLLED ADULTS ONLY. ACROSS THE STUDIES, BOTH THE 50 AND 100 MILLIGRAM DOSES OF LITFULO DELIVERED SIGNIFICANT, CLINICALLY MEANI.

PFIZER ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR LITFULO IN PATIENTS WITH NONSEGMENTAL VITILIGO

DATA INDICATE THAT THE 2026-2027 COVID-19 VACCINE FORMULA, TARGETING THE XFG VARIANT, INDUCES A STRONG IMMUNE RESPONSE AGAINST CONTEMPORARY CIRCULATING AND EMERGING LINEAGES MORE THAN FIVE BILLION DOSES OF THE PFIZER-BIONTECH COVID-19 VACCINES DISTRIBUTED GLOBALLYVACCINE DEMONSTRATES A FAVORABLE SAFETY AND EFFICACY PROFILE SHIPPING WILL BEGIN SOON TO ENSURE RAPID ACCESS OF THIS SEASON'S VACCINE NEW YORK AND MAINZ, GERMANY, JULY 29, 2026 - PFIZER INC.

EUROPEAN COMMISSION AUTHORIZES PFIZER AND BIONTECH XFG-ADAPTED COVID-19 VACCINE IN THE EUROPEAN UNION

DATEN ZEIGTEN, DASS DIE COVID-19-IMPFSTOFFFORMULIERUNG FR DAS JAHR 2026-2027, DIE GEGEN DIE XFG-VARIANTE GERICHTET IST, EINE STARKE IMMUNANTWORT GEGEN DERZEIT ZIRKULIERENDE UND NEU AUFTRETENDE VIRUSVARIANTEN GENERIERTBER FNF MILLIARDEN DOSEN DER PFIZER-BIONTECH COVID-19-IMPFSTOFFE WURDEN BEREITS WELTWEIT ZUR VERFGUNG GESTELLTDER IMPFSTOFF ZEIGT EIN VORTEILHAFTES SICHERHEITS- UND WIRKSAMKEITSPROFILDER VERSAND WIRD ZEITNAH BEGINNEN, UM EINEN SCHNELLEN ZUGANG ZU DEM IMPFSTOFF DER AKTUELLEN SAISON ZU GEWHRLEISTEN NEW YORK UND MAINZ, DEUTSCHLAND, 29.

EUROPISCHE KOMMISSION GENEHMIGT MARKTZULASSUNG DES AN XFG ANGEPASSTEN COVID-19-IMPFSTOFFS VON PFIZER UND BIONTECH  IN DER EUROPISCHEN UNION

NEW YORK--(BUSINESS WIRE)--PFIZER INC. (NYSE: PFE) TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) ACCEPTED FOR PRIORITY REVIEW A SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) FOR TALZENNA (TALAZOPARIB), AN ORAL POLY ADP-RIBOSE POLYMERASE (PARP) INHIBITOR, IN COMBINATION WITH XTANDI (ENZALUTAMIDE), AN ANDROGEN RECEPTOR PATHWAY INHIBITOR (ARPI), IN MEN WITH HOMOLOGOUS RECOMBINATION REPAIR (HRR) GENE-ALTERED METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC), ALSO KNOWN AS META.

FDA GRANTS PRIORITY REVIEW FOR PFIZER'S TALZENNA PLUS XTANDI FOR THE TREATMENT OF METASTATIC PROSTATE CANCER

ARBUTUS AND ITS EXCLUSIVE LICENSEE, GENEVANT, FILED THREE INTERNATIONAL LAWSUITS SEEKING TO ENFORCE PATENTS PROTECTING THEIR INNOVATIVE LIPID NANOPARTICLE (LNP) TECHNOLOGY AGAINST PFIZER AND BIONTECH

ARBUTUS INITIATES INTERNATIONAL PATENT INFRINGEMENT ENFORCEMENT ACTIONS AGAINST PFIZER AND BIONTECH, RECEIVES FIRST PAYMENT FROM MODERNA SETTLEMENT AGREEMENT AND ANNOUNCES INTENT TO RETURN CAPITAL TO SHAREHOLDERS

NEW YORK & TOKYO--(BUSINESS WIRE)--PFIZER INC. (NYSE: PFE) AND ASTELLAS PHARMA INC. (TSE: 4503, PRESIDENT AND CEO: NAOKI OKAMURA, ASTELLAS) TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED PADCEV (ENFORTUMAB VEDOTIN-EJFV), A NECTIN-4 DIRECTED ANTIBODY-DRUG CONJUGATE, PLUS THE PD-1 INHIBITOR, KEYTRUDA (PEMBROLIZUMAB) OR KEYTRUDA QLEX (PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH) AS NEOADJUVANT AND ADJUVANT (BEFORE AND AFTER SURGERY) TREATMENT FOR ADULT PATIENT.

U.S. FDA APPROVES PADCEV PLUS KEYTRUDA AS NEOADJUVANT AND ADJUVANT TREATMENT FOR MUSCLE-INVASIVE BLADDER CANCER REGARDLESS OF CISPLATIN ELIGIBILITY

NEW YORK--(BUSINESS WIRE)--PFIZER INC. (NYSE: PFE) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS DECLARED A $0.43 THIRD-QUARTER 2026 DIVIDEND ON THE COMPANY'S COMMON STOCK, PAYABLE SEPTEMBER 1, 2026, TO HOLDERS OF THE COMMON STOCK OF RECORD AT THE CLOSE OF BUSINESS ON JULY 24, 2026. PFIZER IS COMMITTED TO MAINTAINING, AND OVER THE LONGER TERM, GROWING THE DIVIDEND, AS PART OF ITS CAPITAL ALLOCATION STRATEGY. THE THIRD-QUARTER 2026 CASH DIVIDEND WILL BE THE 351ST CONSECUTIVE QUARTERLY DIVIDEND PAI.

Pfizer Inc.

PFE

Price

Financial Reports

No items found.

Press Releases

Pfizer Inc.

PFE.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

PFE